Oragenics Inc (OGEN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Oragenics Inc (OGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012280
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oragenics Inc (Oragenics) is a biopharmaceutical company that focuses on the development and commercialization of novel antibiotics against infectious disease and develops treatments for oral mucositis. The company develops a new class of potent gram-positive antibiotics which are called Lantibiotics for combating resistant bacterial infections. Its pipeline products include MU1140, being tested for healthcare associated infections caused by drug-resistant bacteria. The company develops other candidates and technologies in the oral care and weight loss areas which include AG013 for the treatment of oral mucositis in cancer patients; OG716 in preclinical phase for healthcare-associated infections; and LPT3-04 for weight loss. Oragenics is headquartered in Tampa, Florida, the US.

Oragenics Inc (OGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oragenics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Intrexon Enters into Co-Development Agreement with Oragenics 10
Oragenics Enters Into Co-Development Agreement With Intrexon 11
Licensing Agreements 13
Oragenics Amends Licensing Agreement with Texas A&M University System 13
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 15
Oragenics Enters Into Licensing Agreement With PharmaForce 17
Equity Offering 18
Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 18
Oragenics Raises USD6.7 Million in Private Placement of Shares 19
Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 20
Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 21
Oragenics Raises USD4.7 Million in Private Placement of Shares 22
Oragenics Completes Public Offering Of Shares For US$11 Million 24
Oragenics Completes Private Placement Of Shares For US$4 Million 25
Oragenics Completes Private Placement Of Common Stock For US$13 Million 26
Asset Transactions 27
Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 27
Oragenics Inc – Key Competitors 28
Oragenics Inc – Key Employees 29
Oragenics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Apr 18, 2017: Oragenics Provides First Quarter 2017 Update 31
Corporate Communications 32
Jun 06, 2016: Oragenics Announces new President, Chief Executive Officer and Member of the Board of Directors 32
Product News 33
08/23/2016: Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections 33
Clinical Trials 34
May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Oragenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oragenics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Intrexon Enters into Co-Development Agreement with Oragenics 10
Oragenics Enters Into Co-Development Agreement With Intrexon 11
Oragenics Amends Licensing Agreement with Texas A&M University System 13
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 15
Oragenics Enters Into Licensing Agreement With PharmaForce 17
Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 18
Oragenics Raises USD6.7 Million in Private Placement of Shares 19
Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 20
Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 21
Oragenics Raises USD4.7 Million in Private Placement of Shares 22
Oragenics Completes Public Offering Of Shares For US$11 Million 24
Oragenics Completes Private Placement Of Shares For US$4 Million 25
Oragenics Completes Private Placement Of Common Stock For US$13 Million 26
Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 27
Oragenics Inc, Key Competitors 28
Oragenics Inc, Key Employees 29
Oragenics Inc, Other Locations 30

★海外企業調査レポート[Oragenics Inc (OGEN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NV Bekaert SA:戦略・SWOT・企業財務分析
    NV Bekaert SA - Strategy, SWOT and Corporate Finance Report Summary NV Bekaert SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • City Holding Co (CHCO):企業の財務・戦略的SWOT分析
    City Holding Co (CHCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Carlsberg Brewery Malaysia Berhad:戦略・SWOT・企業財務分析
    Carlsberg Brewery Malaysia Berhad - Strategy, SWOT and Corporate Finance Report Summary Carlsberg Brewery Malaysia Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Neovacs SA (ALNEV):製薬・医療:M&Aディール及び事業提携情報
    Summary Neovacs SA (Neovacs) is a biotechnology company that develops various therapeutic vaccines for the treatment of autoimmune disorders, inflammatory diseases and cancers. The company offers TNF- kinoid and IFNalpha- kinoid products used for the treatment of rheumatoid arthritis, Crohn’s diseas …
  • Cardiva Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Cardiva Medical Inc (Cardiva) designs, develops and commercializes of vascular access management products. The major products of the company include VASCADE vascular closure system (VCS) for femoral arterial access site closure post-diagnostic and interventional endovascular procedures; and …
  • Rallye SA:戦略・SWOT・企業財務分析
    Rallye SA - Strategy, SWOT and Corporate Finance Report Summary Rallye SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Eutelsat Communications S.A. (ETL):企業の財務・戦略的SWOT分析
    Eutelsat Communications S.A. (ETL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Harley-Davidson Inc (HOG):企業の財務・戦略的SWOT分析
    Harley-Davidson Inc (HOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Daxor Corp (DXR):企業の財務・戦略的SWOT分析
    Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • The Export-Import Bank of Korea:電力:M&Aディール及び事業提携情報
    Summary The Export-Import Bank of Korea (Korea Eximbank) is a bank that offers financial products and services. The company’s products include loans, guarantees, bonds, trade finance products, investment products, and structured products. Its loan products comprise export related loans, overseas bus …
  • Raschig GmbH:企業の戦略的SWOT分析
    Raschig GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • NCC Ltd (NCC):企業の財務・戦略的SWOT分析
    NCC Ltd (NCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Natco Pharma Ltd (NATCOPHARM):製薬・医療:M&Aディール及び事業提携情報
    Summary Natco Pharma Ltd (Natco Pharma) focuses on the research, development, manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage forms in capsule, injection and tablet. Its products are indicated to treat multiple sclerosis, i …
  • Berkley Renewables Inc (BKS)-石油・ガス分野:企業M&A・提携分析
    Summary Berkley Renewables Inc (Berkley) is a venture firm that focuses on capturing opportunities in renewable energy, life sciences, and oil & gas sectors. The company essentially carries out power generation through the management and operation of solar photovoltaic plants . It also undertakes th …
  • The Seibels Bruce Group Inc:企業の戦略・SWOT・財務分析
    The Seibels Bruce Group Inc - Strategy, SWOT and Corporate Finance Report Summary The Seibels Bruce Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Ushdev International Limited (511736)-エネルギー分野:企業M&A・提携分析
    Summary Ushdev International Limited (Ushdev) is a trading company primarily focusing on ferrous and non-ferrous metals. It trades various ferrous and non-ferrous metals including raw materials such as metallurgical coal and coke, steel crap, iron ore-lumps, pi iron, sponge iron, fines, copper scrap …
  • Western & Southern Financial Group, Inc.:戦略・SWOT・企業財務分析
    Western & Southern Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Western & Southern Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Neuraltus Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Neuraltus Pharmaceuticals Inc (Neuraltus) is a biopharmaceutical company that develops and commercializes therapeutics for neurodegenerative diseases. The company offers products under clinical development that include NP001 and others. It develops macrophage which is based on the recent und …
  • Phenex Pharmaceuticals AG-製薬・医療分野:企業M&A・提携分析
    Summary Phenex Pharmaceuticals AG (Phenex) is a drug discovery and development company that offers nuclear receptors for the development of novel therapies. The company offer services which include contract screening services, NR selectivity screening and SNuRM profiling to pharmaceutical, biotechno …
  • Liechtensteinische Landesbank AG:企業の戦略・SWOT・財務情報
    Liechtensteinische Landesbank AG - Strategy, SWOT and Corporate Finance Report Summary Liechtensteinische Landesbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆